|
|
|
|
 |
Aethlon Medical Releases Shareholder Letter |
| Companies mentioned in this article: |
|
Aethlon |
|
| 9/4/2008 @ 2:43 PM
print this article -
email to a friend -
join our eNewsletter
|
 |
Aethlon Medical, Inc. (OTCBB:AEMD) disclosed today that its Chairman and CEO, James A. Joyce has issued the following letter to shareholders.
To our Shareholders,
September 2008 will be a pivotal month for our organization as we expect to initiate the first clinical use of our Hemopurifier in HIV-infected individuals. We believe the Hemopurifier can address the clearance of all HIV strains, thus curbing the proliferation of mutant strains that cause patients to fail their drug regimens. A therapeutic approach able to inhibit drug resistance has long been hoped for by the HIV-AIDS community. We hope to fill that treatment void.
We are also moving towards completion of our human safety study being conducted at the Fortis Hospital in Delhi, India. While the pace of patient enrollment was slower than anticipated, I am pleased to disclose that our treatment protocol has been expanded to include patients infected with Hepatitis-C virus (HCV). As a result, preliminary HCV data, including changes in viral load resulting from Hemopurifier treatment, should be available for dissemination in the coming weeks. The opportunity for new antiviral strategies to fight HCV is significant, as approximately 180 million people worldwide (3% of the world’s population) are HCV infected. According to the World Health Organization (WHO), only 30-50% of infected patients beneficially respond to the established pegylated interferon-ribavirin treatment standard. Recognizing the exceptional challenge in treating HCV, we are cautiously optimistic that human data will reinforce the potential of our Hemopurifier to improve treatment outcomes. Based on the magnitude of the HCV market opportunity, we also recognize that clinical stage organizations with promising HCV treatment candidates have been rewarded with enviable public market valuations.
Beyond pivotal milestone activities expected this month, it should be noted that our team has already been quite productive in 2008. In studies conducted at collaborating research centers, the in vitro effectiveness of our Hemopurifier to rapidly capture highly fatal H5N1 Avian Influenza Virus (bird flu), the reconstructed Spanish Flu Virus of 1918, Monkey Pox Virus, and West Nile Virus have all been documented since the beginning of the year. Thus, further reinforcing the broad-spectrum capabilities of our technology. Additionally, we expanded our robust intellectual property estate; provided a formal response to a pending U.S. government biodefense contract; and have initiated development of a family of pipeline products based on techniques and methods evolved in the creation of our core Hemopurifier technology. This pipeline presently includes therapeutic filtration devices to remove high-dose chemotherapy agents, and growth factors that increase the spread of metastases in cancer.
Thus far in 2008, we have progressed our mission to establish the industry to treat infectious disease and cancer with therapeutic filtration devices. It is my hope that outcomes from near-term human treatment milestones will accelerate the evolution of our organization and establish appropriate shareholder value. On behalf of our team at Aethlon Medical, I thank you for your continued support.
Very truly yours,
James A. Joyce
Chairman, CEO |
| BioTech / BioMedical / Medical |
|
|
| |
| Thursday, December 4, 2008 |
 |
|
VentiRx Pharmaceuticals Commences Phase I Clinical Trial of VTX-2337, a Novel TLR8 Agonist for the Treatment of Oncology Posted 9:48 AM PST
Novio Biomedical and VGX Pharmaceuticals to Highlight Recent Advances in Electroporation-Delivered DVA Vaccines at International DNA Vaccines Conference Posted 7:42 AM PST
Applied Biosystems SOLiD System Named Life Science Innovation of the Year Posted 7:41 AM PST
Ambit Biosciences to Unveil Clinical Data from its AC220 AML Trial at American Society for Hematology Annual Conference Posted 7:37 AM PST
Aperio Introduces SecondSlide Digital Slide Sharing Network Posted 7:33 AM PST
|
| |
| Wednesday, December 3, 2008 |
|
|
Vical Signs Binding Letter of Intent for Sales and Marketing of Allovectin-7 in Turkey Posted 7:19 PM PST
Isis Announces That OGX-011 Has Shown Overall Survival Advantage in Prostate Cancer Compared to Standard Therapy in a Randomized Phase 2 Study Posted 7:15 PM PST
Biocept Awarded Accreditation by the College of American Pathologists Posted 7:13 PM PST
Somaxon Pharmaceuticals to Present at the RBC Capital Markets Healthcare Conference Posted 7:07 AM PST
|
| |
| Tuesday, December 2, 2008 |
|
|
Quidel Authorizes Additional $25 Million under Stock Repurchase Program Posted 4:02 PM PST
First-Ever Human Trial of DNA-Based Immunotherapy Delivered Using Inovio Biomedical’s Electroporation Technology Shows Safety and Durable Systemic Clinical Response Posted 8:54 AM PST
Applied Biosystems – Part of Life Technologies – Helps China Respond to Melamine Contamination in Dairy Products Posted 8:51 AM PST
Nirvanix Plays Supporting Role in Ooyala’s Scalable Video Management Platform Posted 8:49 AM PST
ANA598 Receives Fast Track Designation From the FDA for the Treatment of Chronic Hepatitis C Infection Posted 8:47 AM PST
Genoptix Announces Participation at the RBC Capital Markets 2008 Healthcare Conference Posted 8:25 AM PST
TorreyPines Therapeutics Muscarinic Agonist NGX267 Meets Primary Endpoint in a Phase II Clinical Trial in Patients with Xerostomia Posted 8:24 AM PST
|
| |
| Monday, December 1, 2008 |
|
|
SpectraScience Awarded European Patent for Its Optical Biopsy System for Tissue Diagnosis Posted 4:39 PM PST
Quidel to Present at the 20th Annual Piper Jaffray Healthcare Conference Posted 4:27 PM PST
Next-Generation Noninvasive Diagnostic Technology Shown to Accurately Detect Fetal Down Syndrome in First Trimester of Pregnancy Posted 4:26 PM PST
Novelix Pharmaceuticals, Inc. Initiates Actinic Keratosis Drug Development Program Based on Topical Use of NVX-207 and Expands Intellectual Property Portfolio Posted 4:25 PM PST
Anadys Pharmaceuticals to Present at the Piper Jaffray Health Care Conference Posted 8:49 AM PST
Applied Nanoscience Announces Successful EPA-FIFRA Registration for NanoFense Formulation Posted 8:46 AM PST
Ceregene Announces Clinical Data From Phase 2 Clinical Trial of CERE-120 for Parkinson's Disease Posted 8:45 AM PST
Vical Receives Milestone Payment from Merck & Co., Inc. Triggered by Planned Initiation of Investigational Cancer DNA Vaccine Trial Posted 8:39 AM PST
PURE Bioscience and Ciba Strike New Contract for Natural Antimicrobial Posted 8:36 AM PST
TorreyPines' NGX426, an Oral AMPA/Kainate Receptor Antagonist, Meets Primary Endpoints in Reducing Capsaicin-Induced Pain in Healthy Subjects Posted 8:35 AM PST
DexCom Receives CE Mark Approval for the SEVEN Continuous Glucose Monitoring System European Association for the Study of Diabetes (EASD) meeting Piper Jaffray 20th Annual Health Care Conference Posted 8:29 AM PST
|
| |
| Monday, November 24, 2008 |
|
|
Visage Imaging and Viatronix Sign Comprehensive Marketing Agreement for Virtual Colonoscopy Product Posted 4:27 PM PST
New Noninvasive Prenatal Diagnostic Technology Allows Diagnosis of Inherited Diseases Such as Cystic Fibrosis Caused by Single Gene Mutations Posted 4:23 PM PST
Life Technologies to Present at J.P. Morgan Small/Mid Cap Conference Posted 4:22 PM PST
FDA Extends Review of Somaxon Pharmaceuticals’ New Drug Application for Silenor (Doxepin) by up to Three Months Posted 7:44 AM PST
International Stem Cell Corporation Partners with Absorption Systems to Commercialize Human Stem Cell-Derived Corneal Tissue for Drug Testing Posted 7:40 AM PST
|
|
|
|
|
|
FreshNews.com Jobs Change DAILY
We Have 5,000 + Job Listings! Open Your FREE Account
Employers or Job Searchers Get Started Now! Click Here
|
